Sources and further reading:
- Bridge RNAs direct programmable recombination of target and donor DNA https://www.nature.com/articles/s4158…
- Structural mechanism of bridge RNA-guided recombination https://www.nature.com/articles/s4158…
Category: genetics – Page 196
6y Younger Horvath Epigenetic Age: My Best Data Yet (16-Test Analysis)
Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhDDiscount Links/Affiliates (Ways To Test Yourself, While Also Helping To Support The Channe):…
Gene therapy restores sight with up to 10,000-fold vision improvement
This gene therapy treats LCA1, causing early childhood vision loss, affecting under 100,000 people:
“One patient reported for the first time being able to navigate at midnight outdoors only with the light of a bonfire,” said Cideciyan, who is also co-director of the Center for Hereditary Retinal Degenerations.
The clinical trials were co-led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
The gene therapy (ATSN-101) is specifically designed to target and correct the genetic mutation in the GUCY2D gene. This gene creates vision-imparting proteins. ATSN-101 is “adapted from the AAV5 microorganism.”
Gene Therapy Restores Vision
Summary: A new gene therapy has restored vision in patients with Leber congenital amaurosis type I (LCA1), a rare genetic condition causing blindness. In a small trial, those receiving the highest dose saw up to a 10,000-fold improvement in light sensitivity and significant gains in reading and navigation abilities.
The therapy, developed by researchers, uses a virus-based system to deliver a functioning gene into the retina’s light-sensitive cells. The results show promise for expanding this treatment, with further trials planned to confirm safety and efficacy.
100-fold Improvement in Sight Seen After Gene Therapy Trial
The vision of people with a rare inherited condition that causes them to lose much of their sight early in childhood was 100 times better after they received gene therapy to address the genetic mutation causing it. Some patients even experienced a 10,000-fold improvement in their vision after receiving the highest dose of the therapy, according to researchers from the Perelman School of Medicine at the University of Pennsylvania who co-led the clinical trial published in The Lancet.
“That 10,000-fold improvement is the same as a patient being able to see their surroundings on a moonlit night outdoors as opposed to requiring bright indoor lighting before treatment,” said the study’s lead author, Artur Cideciyan, Ph.D., a research professor of Ophthalmology and co-director of the Center for Hereditary Retinal Degenerations.
“One patient reported for the first time being able to navigate at midnight outdoors only with the light of a bonfire.”
UVA Research Cracks the Autism Code, Making the Neurodivergent Brain Visible
Their…
A multi-university research team co-led by University of Virginia engineering professor Gustavo K. Rohde has developed a system that can spot genetic markers of autism in brain images with 89 to 95% accuracy.
Their findings suggest doctors may one day see, classify and treat autism and related neurological conditions with this method, without having to rely on, or wait for, behavioral cues. And that means this truly personalized medicine could result in earlier interventions.
“Autism is traditionally diagnosed behaviorally but has a strong genetic basis. A genetics-first approach could transform understanding and treatment of autism,” the researchers wrote in a paper published June 12 in the journal Science Advances.
Chinese researchers’ implant genetically modifies brain cells for neuron growth
Chinese scientists have developed a method using genetic engineering to potentially enhance brain-computer interface (BCI) technology by enlarging neurons for better signal transmission.
The researchers, with the Chinese Academy of Sciences’ National Centre for Nanoscience…
Gene sequence could be implanted with electrodes to make neurons larger and easier to ‘read’ in quest for better mind control of devices.
Dr. Angie Burnett, Ph.D. — Program Director, ARIA — Synthetic Plants For A Sustainable Future
Synthetic Plants For A Sustainable Future — Dr. Angie Burnett, Ph.D. — Program Director, Advanced Research + Invention Agency (ARIA)
Dr. Angie Burnett, Ph.D. is Program Director at the Advanced Research and Invention Agency (ARIA — https://www.aria.org.uk/), a UK organization created by an Act of Parliament, and sponsored by the Department for Science, Innovation, and Technology, to fund projects across a full spectrum of R\&D disciplines, approaches, and institutions, per the ARIA mission statement to “Look beyond what exists today to the breakthroughs we’ll need tomorrow”
Prior to this role, Dr. Burnett was a Research Associate in the Department of Plant Sciences, and a former David MacKay Research Associate at Darwin College and Cambridge Zero where her work focused on understanding the response of maize plants to high light and cold temperature stresses, and the genetic basis for stress tolerance, so that breeders can produce plants which are better able to withstand environmental stress.
Dr. Burnett’s background is in plant physiology. She holds a BA from the University of Cambridge and a PhD from the University of Sheffield, where she was awarded the inaugural PhD studentship from the Society for Experimental Biology. Before commencing her role at the University of Cambridge, she worked as a postdoctoral research associate at Brookhaven National Laboratory in the USA and as a Consultant at the Food and Agriculture Organization of the United Nations in Italy.
Important Episode Links.